Report : Middle East & Africa Injection Pen Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Disposable Injection Pens and Reusable Injection Pens), Therapy (Diabetes, Growth Hormone Therapy, Autoimmune Diseases, Fertility, Cancer, and Others Therapy), and End User (Hospitals and Clinics, Home Care, and Others)
At 6.1% CAGR, the Middle East & Africa Injection Pen Market is speculated to be worth US$ 2,872.94 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Middle East & Africa injection pen market was valued at US$ 2,016.10 million in 2022 and is expected to reach US$ 2,872.94 million by 2028, registering an annual growth rate of 6.1% from 2022 to 2028. technological advancements and healthcare waste reduction and increase in biologics patent expiry and use of biosimilars are the critical factors attributed to the Middle East & Africa injection pen market expansion.
There has been a notable growth in the use of injection pen for the treatment of various chronic disorders such as cancer, diabetes, cardiovascular disorders, and multiple sclerosis. Increase in home healthcare has further propelled the demand for injection pens. This has boosted the technological advancement in the injection pens. The manufacturers are focused on developing the next generation smart insulin pen for the delivery of metered insulin dosage. For instance, Medtronic plc launched InPen integrated with real-time Guardian Connect CGM data. InPen is the first and only FDA-cleared smart insulin pen on the market for people on multiple daily injections (MDI). This integrated system provides real-time glucose readings alongside insulin dose information giving users everything they need to manage their diabetes in one view. Rather than switching between apps, users can see all the required information in real time in one view, making it easier to make smarter dosing decisions to manage their sugar levels. Furthermore, the use of artificial intelligence will be the game changer, as it will keep a track of dose, date, and timing of drugs or insulin, which will be beneficial in a long term and helpful for the treatment and management of various conditions. Conventional syringes used for the delivery of insulin and other injectables can be painful and uncomfortable for the patient on daily basis, and it also generate huge quantity of healthcare waste. Around 73% of insulin waste is associated with the use of conventional technology. With the use of injection pen, this waste is reduced to 3.6%, making a huge difference. Therefore, technological advancement and rising demand in the reduction of healthcare wastage are among the trends expected to propel the growth of injection pen market in the coming years.
On the contrary, presence of alternate drug delivery devices and inadequate reimbursement scenario hurdles the growth of Middle East & Africa injection pen market.
Based on type, the Middle East & Africa injection pen market is segmented into disposable injection pens and reusable injection pens. The disposable injection pens segment held 72.6% market share in 2022, amassing US$ 1,464.47 million. It is projected to garner US$ 2,097.46 million by 2028 to expand at 6.2% CAGR during 2022–2028.
Based on therapy, the Middle East & Africa injection pen market is segmented into diabetes therapy, growth hormone therapy, autoimmune diseases therapy, fertility therapy, cancer therapy, and others. The diabetes therapy segment held 52.9% market share in 2022, amassing US$ 1,065.64 million. It is projected to garner US$ 1,525.49 million by 2028 to expand at 6.2% CAGR during 2022–2028.
Based on end user, the Middle East & Africa injection pen market is segmented into hospitals & clinics, home care and others. The home care segment held 53.5% market share in 2022, amassing US$ 1,078.70 million. It is projected to garner US$ 1,555.64 million by 2028 to expand at 6.3% CAGR during 2022–2028.
Based on country, the Middle East & Africa injection pen market is segmented into Saudi Arabia, South Africa, UAE, and the Rest of Middle East & Africa. Our regional analysis states that the Rest of Middle East & Africa captured 31.4% market share in 2022. It was assessed at US$ 633.30 million in 2022 and is likely to hit US$ 893.06 million by 2028, exhibiting a CAGR of 5.9% during the forecast period.
Key players dominating the Middle East & Africa injection pen market are AstraZeneca Plc, Becton Dickinson and Co, Eli Lilly and Co, Gerresheimer AG, Haselmeier GmbH, Merck KGaA, Novo Nordisk AS, Owen Mumford Ltd, Sanofi SA, and Teva Pharmaceutical Industries Ltd among others.
- In 2019, Medtronic and Novo Nordisk have Entered into Agreement to Provide Integrated Digital Solutions for People with Diabetes. This collaboration develops solutions to enable dosing data from Novo Nordisk smart insulin pens to be shared with Medtronic continuous glucose monitoring devices.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: firstname.lastname@example.org